Furthermore, ARID2 and NTRK1 alterations could serve as predictive markers, in the context of other clinical and pathologic findings, as clinicians make management decisions related to CPIs in patients with MCC. The gene discussed is ARID2; the disease is Merkel cell skin cancer.